[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359239-105":59,"doc-detail-359239-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","survival-difference-in-advanced-stage-cervical-and-ovarian-cancer-patients-treated-with-concomitant-modulated-electro-hyperthermia-in-comparison-to-classic-treatment-modalities-results-of-a-pilot-study-and-meta-analysis","Survival Difference in Advanced-Stage Cervical and Ovarian Cancer Patients Treated with Concomitant Modulated Electro-Hyperthermia in Comparison to Classic Treatment Modalities - Results of a Pilot Study and Meta-Analysis","","Modulated electro-hyperthermia (mEHT) is presented as a recent advance in oncological hyperthermia, with prior studies suggesting safety and efficacy, yet lacking meta-analytic synthesis for cervical or ovarian cancer. A single-institute pilot case series and meta-analysis were performed on advanced-stage cervical and ovarian cancer. Meta-analysis identified five studies totaling 160 cervical and 31 ovarian patients, and 175 standard-of-care cervical controls for comparison.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/survival-difference-in-advanced-stage-cervical-and-ovarian-cancer-patients-treated-with-concomitant-modulated-electro-hyperthermia-in-comparison-to-classic-treatment-modalities-results-of-a-pilot-study-and-meta-analysis/359239/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/survival-difference-in-advanced-stage-cervical-and-ovarian-cancer-patients-treated-with-concomitant-modulated-electro-hyperthermia-in-comparison-to-classic-treatment-modalities-results-of-a-pilot-study-and-meta-analysis/359239.png","ImageObject",300,407,{"name":92,"@type":93},"\tJames","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is modulated electro-hyperthermia (mEHT) and how does it work?","Question",{"text":112,"@type":113},"mEHT uses a capacitive coupled impedance matched approach where a 13.56 MHz radiofrequency current is conducted through the target. It can induce local hyperthermia and trigger cellular processes that support immune activation through DAMPs, with an abscopal systemic effect.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was mEHT evaluated in cervical and ovarian cancer patients?",{"text":117,"@type":113},"The study combined a single-institute pilot case series with a meta-analysis. Advanced-stage cervical and ovarian cancer cases were included, with pilot treatments using Oncotherm EHY-2000+ and EHY-2030 devices.",{"name":119,"@type":110,"acceptedAnswer":120},"What survival differences were reported for cervical cancer treated with mEHT compared with classic standard care?",{"text":121,"@type":113},"Meta-analysis showed improved 2-year survival in mEHT-treated cervical cancer cohorts versus controls (78.13% vs 58.86%), with reported odds ratio and p-values indicating statistical significance. The 1- and 2-year survival rates were also reported with confidence intervals.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359239,1790798679,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nSurvival Difference in Advanced-Stage Cervical and Ovarian Cancer Patients Treated with Concomitant Modulated Electro-Hyperthermia in Comparison to Classic Treatment Modalities: Results of a Pilot Study and Meta-Analysis  \nIvan Panczel 1,2, Magdolna Herold 1,2,3, Erika Borbenyi 1, Daniel Horanyi 2, Zoltan Novak 2, Magdolna Dank 1,2,3, Attila Marcell Szasz 1,3,* and Zoltan Herold 1,2,3  \nAcademic Editor: KonstantinosDimas  \n1 Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary  \n2 National Institute of Oncology, H-1122 Budapest, Hungary  \n3 Department of Clinical Oncology, Semmelweis University, H-1122 Budapest, Hungary  \n* Correspondence: [szasz.attila.marcell@semmelweis.hu](szasz.attila.marcell@semmelweis.hu); Tel.: +36-1-459-1500  \nAbstract  \nBackground: Modulated electro-hyperthermia (mEHT) is one of the latest advancementsin the field of oncological hyperthermia. Previous studies investigating mEHT revealed that it is safe and effective; however, no meta-analysis was conducted either in cervical or ovarian cancer. Methods: A single-institute pilot case series and a meta-analysis were conducted. Advanced stage cervical and ovarian cancer cases were included. In the pilot study, mEHT treatments were conducted using the Oncotherm EHY-2000+ and the EHY-2030 devices with 2–3 treatment sessions per week. Results: For the meta-analysis, a total of five studies were identified, with 160 and 31 cervical and ovarian cancer patients, respectively. In addition, 175 standard-of-care-treated cervical cancer patients were also identified as controls. The 1-and 2-year survival rate of the cervical cancer patients treated with mEHT was 87.61%[95% confidence interval (CI): 71.31–100%] and 78.13%(95% CI: 53.02–100%) . Compared to the controls, the 2-year survival rates (78.13% vs. 58.86%) were significantly better in the mEHT-treated cohorts (odds ratio: 0.4143, p = 0.0441; hazard rate: 0.6607, p = 0.0103) . The 1-and 2-year survival rates of ovarian cancer patients were 45.46%(95% CI: 5.97–84.95%) and 32.83%(95% CI: 0–79.57%), respectively. The result of our institutional data strengthened the results of the meta-analysis. Conclusions: Using mEHT, a significantly higher 2-year survival rate can be achieved in cervical cancer. In this setting, a wider testing/application of the modality is warranted. In the case of ovarian tumors, the available knowledge is minimal, and applicability and efficacy studies are urgently needed.  \nKeywords: cervical cancer; concomitant therapy; modulated electro-hyperthermia; ovarian  \nReceived: 7 January 2026  \nRevised: 11 February 2026  \nAccepted: 19 February 2026  \nPublished: 22 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \ncancer; meta-analysis  \n1. Introduction  \nCervical and ovarian malignancies are one of the most frequent cancers arising in women. In 2022, 986,904 new cases emerged, and more than 555,830 deaths occurred worldwide [1] . Despite the major advancements in treatments, the overall survival and patient outlook for these malignancies is still extremely poor, with a 5-year overall survival  \nof 10–40%[2] . This in part is due to the lack of symptoms and limited diagnostic tools to detect malignancies at early stages. Treatment options in advanced-stage diseases include chemo(radio)therapy and hormonal therapies. Moreover, in recent years, various new treatment options also emerged, including but not limited to immunotherapy, targeted gene therapy and hyperthermic methods [3,4] .  \nIn oncology, concomitant hyperthermia is the artificial raising of the temperature of the tumor and its surrounding to 39–42 ◦ C using full-body or regional heating methods [5] . One of the latest advancements in the field is modulated electro-hyperthermia (mEHT) . It relie","cbCaihcG6YLLcchu","https://ap.wps.com/l/cbCaihcG6YLLcchu","pdf",1264025,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is modulated electro-hyperthermia (mEHT) and how does it work?\",\"answer\":\"mEHT uses a capacitive coupled impedance matched approach where a 13.56 MHz radiofrequency current is conducted through the target. It can induce local hyperthermia and trigger cellular processes that support immune activation through DAMPs, with an abscopal systemic effect.\"},{\"question\":\"How was mEHT evaluated in cervical and ovarian cancer patients?\",\"answer\":\"The study combined a single-institute pilot case series with a meta-analysis. Advanced-stage cervical and ovarian cancer cases were included, with pilot treatments using Oncotherm EHY-2000+ and EHY-2030 devices.\"},{\"question\":\"What survival differences were reported for cervical cancer treated with mEHT compared with classic standard care?\",\"answer\":\"Meta-analysis showed improved 2-year survival in mEHT-treated cervical cancer cohorts versus controls (78.13% vs 58.86%), with reported odds ratio and p-values indicating statistical significance. The 1- and 2-year survival rates were also reported with confidence intervals.\"}]","Survival Difference in Advanced-Stage Cervical and Ovarian Cancer Patients Treated with Concomitant Modulated Electro-Hyperthermia in Comparison to Classic Treatment Modalities - Results of a Pilot Study and Meta-Analysis | PDF",1790136494,33]